These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12426785)

  • 41. [Synthesis of octahydroindolo [2,3-a] quinolizine derivatives].
    Xu JY; Zhu CL
    Yao Xue Xue Bao; 1986 Feb; 21(2):102-8. PubMed ID: 3751588
    [No Abstract]   [Full Text] [Related]  

  • 42. [Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models].
    Pereira C; Agostinho P; Moreira PI; Duarte AI; Santos MS; Oliveira CR
    Acta Med Port; 2003; 16(6):401-6. PubMed ID: 15631851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical and Neuropsychological changes associated with vincamin treatment in cerebrovascular disease (author's transl)].
    Ambrozi L; Bruck J; Tschabitscher H
    Nervenarzt; 1982 Mar; 53(3):141-3. PubMed ID: 7078689
    [No Abstract]   [Full Text] [Related]  

  • 44. Cerebral regulation-cerebral regulators.
    Braun P
    Ther Hung; 1980; 28(3):98-104. PubMed ID: 7221974
    [No Abstract]   [Full Text] [Related]  

  • 45. Ethyl apovincaminate therapy in neurovascular diseases.
    Szobor A; Klein M
    Arzneimittelforschung; 1976; 26(10a):1984-9. PubMed ID: 1037230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro characterization of transport and metabolism of the alkaloids: vincamine, vinpocetine and eburnamonine.
    Fandy TE; Abdallah I; Khayat M; Colby DA; Hassan HE
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):259-67. PubMed ID: 26666648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment of circulatory encephalopathy with Cavinton].
    Lebedeva NV; Chukhrova VA; Solov'ev OU; Nepesov RR
    Klin Med (Mosk); 1997; 75(11):51-3. PubMed ID: 9490359
    [No Abstract]   [Full Text] [Related]  

  • 48. Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model.
    Nyakas C; Felszeghy K; Szabó R; Keijser JN; Luiten PG; Szombathelyi Z; Tihanyi K
    CNS Neurosci Ther; 2009; 15(2):89-99. PubMed ID: 19492990
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and evaluation of 2'-hydroxyethyl trans-apovincaminate derivatives as antioxidant and cognitive enhancer agents.
    Nemes A; Czibula L; Szántay C; Gere A; Kiss B; Laszy J; Gyertyán I; Szombathelyi Z; Szántay C
    J Med Chem; 2008 Feb; 51(3):479-86. PubMed ID: 18183943
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Open-labeled phase III clinical trials with vinpocetine in Japan.
    Ebi O
    Ther Hung; 1985; 33(1):41-9. PubMed ID: 3915913
    [No Abstract]   [Full Text] [Related]  

  • 51. Cerebral antioedematous effect of Teproside and of some vincamine derivatives.
    Borzeix MG; Cahn J
    Int J Clin Pharmacol Res; 1984; 4(4):259-61. PubMed ID: 6500773
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cavinton in the treatment of acute stroke.
    Kovács L
    Ther Hung; 1985; 33(1):50-7. PubMed ID: 3841999
    [No Abstract]   [Full Text] [Related]  

  • 53. [Effect of vinpocetine on cerebral circulation in rats after exposure to radiation].
    Vereshchagin VK
    Eksp Klin Farmakol; 2003; 66(5):14-6. PubMed ID: 14650207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Chronic disorders of cerebral blood circulation: possibilities of the use of cavinton].
    Kamchatnov PR; Zaĭtsev KA; Chugunov AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(4 Suppl 2):52-6. PubMed ID: 20740716
    [No Abstract]   [Full Text] [Related]  

  • 55. [A multicenter program on assessment of efficacy and safety of a new therapeutic scheme for patients with chronic cerebrovascular insufficiency].
    Skoromets AA; Tanashian MM; Chukanova EI; Petrova EA; Spirin NN; Nikonov AA; Peverennova IE; Levin IaI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5 Suppl 2):44-8. PubMed ID: 19894300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Cerebral hemodynamic function in patients with the initial manifestations of brain blood supply failure under the influence of pelotherapy combined with the electrophoresis of vasoactive preparations].
    Musaev AV; Balakishieva FK
    Vopr Kurortol Fizioter Lech Fiz Kult; 1991; (4):13-6. PubMed ID: 1792718
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute i.v. vincamine teprosilate administration: quantified investigation in elderly subjects.
    Moglia A; Alfonsi E; Zandrini C; Pistarini C; Arrigo A
    Int J Clin Pharmacol Res; 1984; 4(4):303-6. PubMed ID: 6500777
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Use of a cerebral oxygenator drug in chronic encephalopathies (apropos of the trial of vincamine)].
    Fossey F; Pasquier C
    Rev Neuropsychiatr Infant; 1972; 20(11):887-91. PubMed ID: 4650072
    [No Abstract]   [Full Text] [Related]  

  • 59. [Effect of a series of vasoactive drugs on the compensatory adaptive processes of the brain during acute experimental cerebral venous stasis].
    Berdichevskiĭ MIa; Onopchenko NV; Dronnikova IS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(8):1178-81. PubMed ID: 3673412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the effect of vincamine teprosilate on behavioural performances of patients affected with chronic cerebrovascular disease.
    Casale R; Giorgi I; Guarnaschelli C
    Int J Clin Pharmacol Res; 1984; 4(4):313-9. PubMed ID: 6500778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.